Conditions: Rhabdomyosarcoma Malignant Peripheral Nerve Sheath Tumors Chondrosarcoma Sarcoma, Ewing's Sarcoma, Alveolar Soft Part Chordoma Epithelioid Sarcoma Giant Cell Tumor of Bone Hemangiopericytoma Gastrointestinal Stromal Tumor (GIST)
Keywords: Dasatinib Rhabdomyosarcoma Malignant peripheral nerve sheath tumor Chondrosarcoma Ewing's Alveolar soft part sarcoma (ASPS) Chordoma Epithelioid sarcoma Giant cell tumor of bone Hemangiopericytoma/solitary fibrous tumor Gastrointestinal Stromal Tumor (GIST)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 366
Healthy volunteers: no

Brief summary:
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Detailed description:
Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle.

Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment.

A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment.

Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur.

Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration.

Arms:
arm 1: Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles

Interventions: intervention 1: Dasatinib
Intervention descriptions: intervention 1: oral agent, continuous dosing, Cycles = 28 days

Protocol document: